Protocol Review &Monitoring System The Protocol Review &Monitoring System (PRMS) at Moffitt Cancer Center facilitates the function of two Scientific Review Committees (SRCs), each staffed with appropriate faculty and scientific representation. Each committee meets once a month, with staggered meetings so that there is an SRC meeting approximately every two weeks. The SRCs provide the review for scientific merit and prioritization and monitor scientific progress for all protocols at the Cancer Center. SRC approval is required prior to IRB submission and the IRB will not consider a research study from the Cancer Center that has not been approved by the Moffitt Cancer Center SRC. The SRCs have reviewed between 180 and 200 new protocols each year of the grant for scientific merit. Protocols that have been previously peer reviewed by recognized peer-review agencies are expedited through the SRC process, but are reviewed administratively by the Chair or his designee. The committees review all ongoing clinical research studies for scientific progress and have the authority to suspend and close studies that are not making scientific progress towards their objectives. The Cancer Center is in the process of implementing the Oncore? clinical trials management software that will aid the PRMS in the administrative tracking of all research studies (pending and ongoing), as well as facilitate the committee process by helping to coordinate the committee membership, agendas, decisions and correspondence.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-13
Application #
8214126
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
13
Fiscal Year
2011
Total Cost
$124,318
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Davis, Stacy N; Christy, Shannon M; Chavarria, Enmanuel A et al. (2017) A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics. Cancer 123:1390-1400
Song, Jinming; Hussaini, Mohammad; Zhang, Hailing et al. (2017) Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. Am J Clin Pathol 147:444-452
Tauro, Marilena; Shay, Gemma; Sansil, Samer S et al. (2017) Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth. Mol Cancer Ther 16:494-505
Heit, Claire; Marshall, Stephanie; Singh, Surrendra et al. (2017) Catalase deletion promotes prediabetic phenotype in mice. Free Radic Biol Med 103:48-56
Eksioglu, E A; Chen, X; Heider, K-H et al. (2017) Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia 31:2172-2180
Strom, Tobin; Harrison, Louis B; Giuliano, Anna R et al. (2017) Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer 84:304-314
Liu, Ying; Balagurunathan, Yoganand; Atwater, Thomas et al. (2017) Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules. Clin Cancer Res 23:1442-1449
Chen, Yi; Fisher, Kate J; Lloyd, Mark et al. (2017) Multiplexed Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry Quantification of Cancer Signaling Proteins. Methods Mol Biol 1647:19-45
Kamath, Vidya P; Torres-Roca, Javier F; Eschrich, Steven A (2017) Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity. Int J Genomics 2017:6576840
Ahmed, Kamran A; Berglund, Anders E; Welsh, Eric A et al. (2017) The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity. Neuro Oncol 19:1145-1146

Showing the most recent 10 out of 1137 publications